ERBB2 and breast cancer: With the aim of identifying a better drug than trastuzumab, the phase III SOPHIA trial tested margetuximab with chemotherapy versus trastuzumab with chemotherapy in metastatic HER2+ BC patients who were previously heavily treated [136].